CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ra Pharmaceuticals, Inc. (NASDAQ: RARX), a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for the treatment of complement-mediated diseases, today announced financial results for the first quarter ended March 31, 2017 and provided an update on recent corporate and clinical developments.
“We continue to advance our lead compound, RA101495, and we recently commenced dosing in our Phase 2 program in paroxysmal nocturnal hemoglobinuria, or PNH,” said Doug Treco, PhD, President and Chief Executive Officer of Ra Pharma. “The goal of our program in PNH is to provide sustained and improved disease control, which reduces the risk of breakthrough hemolysis, while simultaneously offering patients a more convenient and flexible subcutaneous treatment regimen as a substitute for intravenous administration, today’s standard of care. We look forward to sharing initial data from these Phase 2 studies mid-year 2017 and additional results at year-end.”
Dr. Treco added: “We are also investigating RA101495 in other complement-mediated diseases such as myasthenia gravis (MG) and lupus nephritis (LN). We plan to initiate a Phase 2 trial in MG and a Phase 1b clinical trial supporting development in LN in the second half of 2017. We look forward to updating you on our RA101495 development plans, our orally-available small molecule C5 inhibitors and other pipeline programs.”
